Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility
- 1 July 2019
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 76 (1) , 24-26
Abstract
No abstract availableFunding Information
- New York Community Trust
This publication has 9 references indexed in Scilit:
- Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate CancerEuropean Urology, 2019
- Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance ImagingEuropean Urology, 2019
- Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic studyThe Lancet Oncology, 2019
- Prostate Cancers Detected by Magnetic Resonance Imaging–Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical ProstatectomiesArchives of Pathology & Laboratory Medicine, 2018
- Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform CarcinomaJournal of Urology, 2018
- A Prostate Cancer “ Nimbosus ”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform SubpathologiesEuropean Urology, 2017
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory studyThe Lancet, 2017
- Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount HistopathologyEuropean Urology, 2015
- Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate CancerJAMA, 2015